Tribbles in acute leukemia

Blood

Volumn 121, Issue 21, 2013, Pages 4265-4270

  Liang, Kai Ling ^a   Rishi, Loveena ^b   Keeshan, Karen ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; PROTEIN SERINE THREONINE KINASE; TRIBBLE 1 PROTEIN; TRIBBLE 2 PROTEIN; TRIBBLE 3 PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; TRIB1 PROTEIN, HUMAN; TRIB2 PROTEIN, HUMAN; TRIB3 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; CANCER CHEMOTHERAPY; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; ACUTE GRANULOCYTIC LEUKEMIA; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

CELL CYCLE PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84880408795     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471300     Document Type: Review

References (42)

1. Hegedus Z, Czibula A, Kiss-Toth E. Tribbles: a family of kinase-like proteins with potent signalling regulatory function. Cell Signal. 2007; 19(2):238-250.
2. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309.
3. Hebestreit K, Gröttrup S, Emden D, et al. Leukemia gene atlas: a public platform for integrative exploration of genome-wide molecular data. PLoS ONE. 2012;7(6):e39148.
4. Satoh T, Kidoya H, Naito H, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 2013;495(7442):524-528.
5. Mancini E, Sanjuan-Pla A, Luciani L, et al. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 2012;31(2):351-365.
6. Bagger FO, Rapin N, Theilgaard-Mönch K, Kaczkowski B, Jendholm J, Winther O, Porse B. HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood. 2012;119(26):6394-6395.
7. Röthlisberger B, Heizmann M, Bargetzi MJ, Huber AR. TRIB1 overexpression in acute myeloid leukemia. Cancer Genet Cytogenet. 2007;176(1):58-60.
8. Storlazzi CT, Fioretos T, Paulsson K, et al. Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies. Hum Mol Genet. 2004;13(14):1479-1485.
9. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004; 350(16):1617-1628.
10. Gutiérrez NC, López-Pérez R, Hernández JM, et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia. 2005;19(3): 402-409.
11. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
12. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15):2529-2537.
13. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011; 17(9):1086-1093.
14. Jin G, Yamazaki Y, Takuwa M, et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007;109(9):3998-4005.
15. Dedhia PH, Keeshan K, Uljon S, et al. Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia. Blood. 2010;116(8):1321-1328.
16. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood. 2010; 116(15):2768-2775.
17. Yokoyama T, Toki T, Aoki Y, et al. Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood. 2012;119(11):2608-2611.
18. Keeshan K, He Y, Wouters BJ, et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell. 2006; 10(5):401-411.
19. Keeshan K, Bailis W, Dedhia PH, et al. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood. 2010;116(23):4948-4957.
20. Gilby DC, Sung HY, Winship PR, Goodeve AC, Reilly JT, Kiss-Toth E. Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia. Immunol Lett. 2010;130(1-2):115-124.
21. Figueroa ME, Wouters BJ, Skrabanek L, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 2009;113(12):2795-2804.
22. Wouters BJ, Jordà MA, Keeshan K, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706-3714.
23. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
24. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA. 2002;99(12):8283-8288.
25. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005; 105(12):4792-4799.
26. Choudhary C, Schwäble J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265-273.
27. Argiropoulos B, Palmqvist L, Yung E, et al. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Exp Hematol. 2008;36(7):845-859.
28. Pineault N, Abramovich C, Humphries RK. Transplantable cell lines generated with NUP98-Hox fusion genes undergo leukemic progression by Meis1 independent of its binding to DNA. Leukemia. 2005;19(4): 636-643.
29. Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101(11):4529-4538.
30. Keeshan K, Shestova O, Ussin L, Pear WS. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. Blood Cells Mol Dis. 2008;40(1): 119-121.
31. Hannon MM, Lohan F, Erbilgin Y, et al. Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL. Br J Haematol. 2012; 158(5):626-634.
32. Heng TS, Painter MW; Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008;9(10):1091-1094.
33. Nagel S, Venturini L, Przybylski GK, et al. Activation of Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52(7):1348-1359.
34. Sanda T, Lawton LN, Barrasa MI, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):209-221.
35. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
36. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.
37. Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood. 2011;118(6):1579-1590.
38. Bijl J, Krosl J, Lebert-Ghali CE, Vacher J, Mayotte N, Sauvageau G. Evidence for Hox and E2A-PBX1 collaboration in mouse T-cell leukemia. Oncogene. 2008;27(49):6356-6364.
39. Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood. 2000;96(5):1906-1913.
40. Thorsteinsdottir U, Krosl J, Kroon E, Haman A, Hoang T, Sauvageau G. The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells. Mol Cell Biol. 1999;19(9):6355-6366.
41. Grandinetti KB, Stevens TA, Ha S, et al. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα. Oncogene. 2011;30(30):3328-3335.
42. Yokoyama T, Nakamura T. Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation. Cancer Sci. 2011;102(6):1115-1122.